The latest industry to face President-elect Trump’s attention is pharmaceutical manufacturing, where a commitment has been made to cut costs. While it is not clear how this will be achieved, the U.S. has made significant use of imported generic drugs once branded versions’ patents end. Panjiva... Read more →